Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-053 with Standard of Care in Newly Diagnosed Glioblastoma
NCT04967690Phase 1Not yet recruiting
- Sponsor
- Double Bond Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Polymer-based Nanoparticles, Hydrogel Systems, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Temodex in glioblastoma (GBM), sponsored by Double Bond Pharmaceutical. Primary endpoints: Incidence rate and grade of dose-limiting toxicities at 6 months and Adverse Events at 6 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
Temodex
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04967690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967690.